The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Recent Advances in Anti-Obesity Agents

비만 약물 치료의 최신 지견

  • Kim, Min Kyung (Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangdong Sacred Heart Hospital) ;
  • Kim, Chul Sik (Division of Endocrinology and Metabolism, Department of Internal Medicine, Hallym University Sacred Heart Hospital)
  • 김민경 (강동성심병원 내분비내과) ;
  • 김철식 (한림대학교성심병원 내분비내과)
  • Received : 2018.10.04
  • Accepted : 2018.10.23
  • Published : 2018.12.01
⟨ Previous Next ⟩

Abstract

Obesity is a chronic disorder that is a significant risk factor for diabetes, cardiovascular diseases, malignancy, and other chronic diseases. Lifestyle modifications form the basis of most treatments for obesity, but it has become clear that such modifications alone are not enough for many obese patients. When a behavioral approach is insufficient, pharmacological treatment may be recommended. In recent years, the US Food and Drug Administration (FDA) has withdrawn several therapeutic options for obesity due to their side effects, but has approved four novel anti-obesity agents. Until recently, orlistat was the only drug approved for the management of long-term obesity, but the US FDA approved the novel anti-obesity drugs lorcaserin and phentermine/topiramate in 2012, and naltrexone/bupropion and liraglutide in 2014. The present review discusses the different pharmacotherapeutic options for the treatment of obesity.

Keywords

References

  1. Haslam DW, James WP. Obesity. Lancet 2005;366:1197-1209. https://doi.org/10.1016/S0140-6736(05)67483-1
  2. World Health Organization. Obesity: preventing and managing the global epidemic. Geneva: World Health Organization, 2000.
  3. Tsigos C, Hainer V, Basdevant A, et al. Management of obesity in adults: European clinical practice guidelines. Obes Facts 2008;1:106-116. https://doi.org/10.1159/000126822
  4. James WP. The epidemiology of obesity: the size of the problem. J Intern Med 2008;263:336-352. https://doi.org/10.1111/j.1365-2796.2008.01922.x
  5. Hensrud DD. Pharmacotherapy for obesity. Med Clin North Am 2000;84:463-476. https://doi.org/10.1016/S0025-7125(05)70231-5
  6. Kim MK, Lee WY, Kang JH, et al. 2014 clinical practice guidelines for overweight and obesity in Korea. Endocrinol Metab (Seoul) 2014;29:405-409. https://doi.org/10.3803/EnM.2014.29.4.405
  7. Vetter ML, Faulconbridge LF, Webb VL, Wadden TA. Behavioral and pharmacologic therapies for obesity. Nat Rev Endocrinol 2010;6:578-588. https://doi.org/10.1038/nrendo.2010.121
  8. Rosenbaum M, Goldsmith R, Bloomfield D, et al. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J Clin Invest 2005;115:3579-3586. https://doi.org/10.1172/JCI25977
  9. Goldsmith R, Joanisse DR, Gallagher D, et al. Effects of experimental weight perturbation on skeletal muscle work efficiency, fuel utilization, and biochemistry in human subjects. Am J Physiol Regul Integr Comp Physiol 2010;298:R79-R88. https://doi.org/10.1152/ajpregu.00053.2009
  10. Soleymani T, Daniel S, Garvey WT. Weight maintenance: challenges, tools and strategies for primary care physicians. Obes Rev 2016;17:81-93.
  11. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-588. https://doi.org/10.1056/NEJM199708283370901
  12. James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010;363:905-917. https://doi.org/10.1056/NEJMoa1003114
  13. Committee of treatment guideline of Korean Society for the Study of Obesity. Guideline of treatment of obesity 2018. 6th ed. Seoul: Cheong Woon, 2018.
  14. Bray GA, Ryan DH. Medical therapy for the patient with obesity. Circulation 2012;125:1695-1703. https://doi.org/10.1161/CIRCULATIONAHA.111.026567
  15. McNeely W, Benfield P. Orlistat. Drugs 1998;56:241-249;discussion 250. https://doi.org/10.2165/00003495-199856020-00007
  16. Drew BS, Dixon AF, Dixon JB. Obesity management: update on orlistat. Vasc Health Risk Manag 2007;3:817-821.
  17. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-161. https://doi.org/10.2337/diacare.27.1.155
  18. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007;335:1194-1199.
  19. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000;9:160-167. https://doi.org/10.1001/archfami.9.2.160
  20. Thomsen WJ, Grottick AJ, Menzaghi F, et al. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther 2008;325:577-587. https://doi.org/10.1124/jpet.107.133348
  21. Weissman NJ, Tighe JF Jr, Gottdiener JS, Gwynne JT. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-release dexfenfluramine study group. N Engl J Med 1998;339:725-732. https://doi.org/10.1056/NEJM199809103391103
  22. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010;363:245-256. https://doi.org/10.1056/NEJMoa0909809
  23. Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 2011;96:3067-3077. https://doi.org/10.1210/jc.2011-1256
  24. O'Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring) 2012;20:1426-1436. https://doi.org/10.1038/oby.2012.66
  25. Bohula EA, Wiviott SD, McGuire DK, et al. Cardiovascular safety of lorcaserin in overweight or obese patients. N Engl J Med 2018;379:1107-1117. https://doi.org/10.1056/NEJMoa1808721
  26. Caixas A, Albert L, Capel I, Rigla M. Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date. Drug Des Devel Ther 2014;8:1419-1427.
  27. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010;376:595-605. https://doi.org/10.1016/S0140-6736(10)60888-4
  28. Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity- related risk factors (COR-II). Obesity (Silver Spring) 2013;21:935-943. https://doi.org/10.1002/oby.20309
  29. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) 2011;19:110-120. https://doi.org/10.1038/oby.2010.147
  30. Smith SR, Fujioka K, Gupta AK, et al. Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity. Diabetes Obes Metab 2013;15:863-866. https://doi.org/10.1111/dom.12095
  31. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373:11-22. https://doi.org/10.1056/NEJMoa1411892
  32. Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA 2015;314:687-699. https://doi.org/10.1001/jama.2015.9676
  33. Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes (Lond) 2013;37:1443-1451. https://doi.org/10.1038/ijo.2013.120
  34. Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE sleep apnea randomized clinical trial. Int J Obes (Lond) 2016;40:1310-1319. https://doi.org/10.1038/ijo.2016.52
  35. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311-322. https://doi.org/10.1056/NEJMoa1603827
  36. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:1341-1352. https://doi.org/10.1016/S0140-6736(11)60205-5
  37. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 2012;20:330-342. https://doi.org/10.1038/oby.2011.330
  38. Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1906-1913. https://doi.org/10.1016/S0140-6736(08)61525-1
  39. O'Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet 2018;392:637-649. https://doi.org/10.1016/S0140-6736(18)31773-2
  40. Kim GW, Lin JE, Blomain ES, Waldman SA. Antiobesity pharmacotherapy: new drugs and emerging targets. Clin Pharmacol Ther 2014;95:53-66.
  41. Khera R, Murad MH, Chandar AK, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA 2016;315:2424-2434. https://doi.org/10.1001/jama.2016.7602

Cited by

  1. 마황이 포함된 한방비만 처방과 Lorcaserin 병용 투여 후 호전된 비만 환자 치험 2예 vol.19, pp.1, 2018, https://doi.org/10.15429/jkomor.2019.19.1.79
  2. 산사의 장내 미생물 조절을 통한 항비만 효과 vol.29, pp.4, 2018, https://doi.org/10.18325/jkmr.2019.29.4.15
  3. Electroacupuncture Treatment for Women with Primary Obesity: A Review of Randomized Controlled Trials vol.37, pp.2, 2018, https://doi.org/10.13045/jar.2020.00136
  4. 과체중 및 비만 환자의 체중감량을 위한 식사량 조절 및 복합 한약 단기 치료(5일 레스큐 프로그램)의 효과와 안전성: 진료기반 연구 vol.20, pp.2, 2018, https://doi.org/10.15429/jkomor.2020.20.2.122
  5. 방풍통성산 및 대시호탕의 항비만효과 분석: 단일기관 무작위배정 이중맹검 임상시험 프로토콜 vol.20, pp.2, 2018, https://doi.org/10.15429/jkomor.2020.20.2.138
  6. 폴리페놀 함량과 항산화력에 따른 피땅콩 겉껍질의 최적 추출 조건 확립과 항비만 기능성 평가 vol.54, pp.1, 2018, https://doi.org/10.4163/jnh.2021.54.1.116